MOESM1 of Comprehensive characterization of the patient-derived xenograft and the paralleled primary hepatocellular carcinoma cell line Phyllis Cheung Chi Yip Linda Ng Kwok Lo Chit Chow Kui Chan Tan Cheung Siu Cheung 10.6084/m9.figshare.c.3646157_D3.v1 https://springernature.figshare.com/articles/journal_contribution/MOESM1_of_Comprehensive_characterization_of_the_patient-derived_xenograft_and_the_paralleled_primary_hepatocellular_carcinoma_cell_line/4474301 Additional file 1: Figure S1. PDX and cell line establishment from fresh HCC tumor specimens. Experimental workflow of establishing PDXs and primary cell lines from HCC patients was illustrated. Fresh tumor tissues were collected from 24 HCC patients and subject to enzymatic digestion by collagenase to release disaggregated cells. Only cells with viability >70% (11 out of 24 cases) were subject to subsequent cell sorting for GEP-expressing cells. For in vivo PDX establishment, GEP-enriched cells were inoculated with 50% matrigel (v/v) subcutaneously at the dorsal region of the trunk of NOD/SCID mice (11 cases). 4 out of 11 cases generated xenograft tumors. NOD/SCID mice inoculated with cells from HCC40 (10 weeks post-inoculation) was shown, while the lower panel shows the corresponding xenograft tumor (HCC40-PDX). For in vitro primary cell line establishment, cells were either seeded onto gelatin-coated plate in hepatocyte culture medium (HCM) (11 cases), or ultra-low attachment plate in serum-free, stem cell-promoting medium for spheroid formation (3 cases). 3 out of 11 cases generated cells that could attach and grow within 1 month. The phase contrast microscopy image showed the cells derived from patient HCC40. For spheroid culture, spheroids formed in all 3 cases after 1-month culture. Spheroids derived from patient HCC40 were shown. The spheroids were dissociated to disaggregated cells, which were then seeded onto culture plate in serum-supplemented medium to induce differentiation of cells to grow into adherent monolayer. The adherent cells grew from spheroids derived from patient #40 was designated as HCC40-CL. 2016-06-08 05:00:00 Hepatocellular carcinoma Cell line establishment Patient-derived xenograft